摘要
近几年,免疫检查点抑制剂疗法飞速发展并取得突破性进展,成为多种晚期肿瘤的首选疗法。但由于其激活抗肿瘤免疫系统的独特作用模式,多种非常规缓解模式相继出现,如延迟反应和假性进展等,给传统疗效评价标准带来挑战,进而促使人们不断探索应对免疫治疗特殊反应的评价指南。本文主要对实体肿瘤多种免疫治疗相关疗效评价标准的探索进程、研究进展及各指南间异同进行系列阐述,并对其目前的挑战和未来发展趋势进行展望。
In recent years, therapy of immune checkpoint inhibitors have developed rapidly and made breakthrough, becoming the first-line treatment for many types of advanced cancer. However, due to its particular mode in activating the anti-tumor immune system, a variety of unconventional response patterns have emerged, such as delayed response and pseudoprogression, which have challenged the traditional response evaluation criteria and encouraged people to continuously explore new criteria for evaluating the unconvention- al response patterns under immunotherapy. This article mainly reviews the process of exploration, advanced research,as well as similari- ties and differencesamongvarious immune-related efficacy evaluation criteria, and finally prospects the current challenges and future trends.
作者
白日兰
崔久嵬
BAI Rilan;CUI Jiuwei(Cancer Center,the First Hospital of Jilin University,Changchun 130021,Jilin,China)
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2018年第7期663-668,共6页
Chinese Journal of Cancer Biotherapy
基金
国家重点研发项目(No.2016YFC1303804)
国家自然科学基金资助项目(No.81672275)
吉林省科技厅重点实验室建设项目(No.20170622011JC)
吉林省发展和改革委员会专项(No.2017C022)
国家卫生计生委专项(No.ZX-07-C2016004)~~
关键词
实体肿瘤
肿瘤免疫治疗
假性进展
疗效评价标准
solid tumor
tumor immunotherapy
pseudoprogression
response evaluation criteria
